There was record attendance at the 30th annual WFH Congress, which took place July 8-12, 2012, in Paris, France. Two of the key objectives of the Congress were to challenge the community to rethink models of care as well as to fi nd ways to involve more of the youth population. Working off these objectives, the topics that gained attention were the use of ultrasound to detect bleeds in patients and the advent of “exergaming” to increase patients’ musculoskeletal capacity.

A recent WFH study concluded that ultrasound may be helpful in the diagnosis of hemarthrosis in patients with hemophilia. In fact, in US exams of 100 patients with hemophilia, 100% of ankle and elbow (as well as 72% of knee) hemarthroses were detected using ultrasound (hemarthrosis is defi ned as bleeding into joint spaces). Up to 25% of all severe ligament or capsular knee injuries leading to hemarthroses are associated with cartilage damage that can lead to progressive degenerative arthritis. Thus, early detection of this condition is necessary to combat it.

These fi ndings are a positive indicator that a new way of determining the presence of hemarthrosis could be here.Querol F, Pérez-Alenda S, Jaca M, Aznar JA. Ultrasonography protocol for diagnosis and control of acute hemarthrosis in haemophilic patients. Poster number 199, presented at: World Federation of Hemophilia 2012 World Congress; July 8-12, 2012; Paris, France. Available at: http://www.postersessiononline.com/173580348_eu/congresos/WFH2012/aula/-We_199_WFH2012.pdf. Accessed August 9, 2012.

The topic of “exergaming”was discussed through several multidisciplinary sessions that addressed the unique needs of the youth community. Today, young patients with hemophilia tend to lead increasingly more sedentary lives, thanks in part to their proclivity for video games. Rather than make an attempt to combat this lifestyle, researchers have come up with a unique solution that incorporates exercise—affectionately dubbed “exergaming.” At the WFH Congress, exergaming was reported to have increased proprioceptive and musculoskeletal capacity in patients with hemophilia. In fact, twice-weekly sessions of 50 minutes were associated with balance and gait improvements as well as increased functional independence. Looking forward, this combination of activities may represent an avenue to engage young hemophilia patients in ways that can greatly improve their health.

da Silva JBJ, Fagnani R, da Silva EOZ, Matta MAP, Ozelo MC. Use of the exergaming (nintendo Wii™ system) in the rehabilitation of patients with hemophilia. Poster number 243, presented at: World Federation of Hemophilia 2012 World Congress; July 8-12, 2012; Paris, France. Available at: http://www.postersessiononline.com/173580348_eu/congresos/WFH2012/aula/-We_243_WFH2012.pdf. Accessed August 9, 2012.

Overall, the robust Congress also included discussions around WFH research initiatives, developing models of hemophilia care, and aging with hemophilia, among other topics. For access to webcasts of selected abstracts, visit wfh.org.

EvENTShemophilia events of note:

THE LATEST FINDINGS FROM WFH

• NHF Annual MeetingNovember 8-10 (orlando, FL)

• 54th ASH Annual Meeting and Exposition December 8-11 (atlanta, Ga)

For more information, please visit Pfi zerHemophilia.com Fall 2012

How Can You Help?Education for caregivers of adults with hemophilia. Covers the basics of hemophilia and discusses practical issues such as safety, travel, andlife transitions.

Encouraging Early IndependenceDiscusses parental attitudes toward their children’s illness and provides guidelines for transitioning infusion responsibility.

Strength in NumbersHighlights the importance of maintaining a healthy lifestyle for hemophilia patients.

Basics of HemophiliaProvides caregivers with information on the science of hemophilia, prevalence, and the history of treatment.

Healthy Lifestyle Choices: The Role of Medication AdherenceDiscusses the importance of adherence to treatment.

New Horizons for Older AdultsFocuses on the challenges older adults with hemophilia face, including fi nancial planning, long-term care, and changes in their support system.

Overcoming ChallengesDiscusses a range of topics relevant to hemophilia patients and their caregivers, including how to cope with chronic illness, how to best communicate with the health care team and others, and the fi nancial considerations of health care as the patient advances through life’s stages.

ADDiTiONAL SUPPOrT FrOM cOMMUNiTY NUrSE EDUcATOrS (cNE)A nurse-led presentation series designed to help facilitate conversation between health care providers, patients, and caregivers. Ask your Pfi zer Hemophilia representative for more information.

The World Federation of Hemophilia (WFH), an international not-for-profi t organization, was established in 1963. It is a global network of patient organizations in over 120 countries and has offi cial recognition from the World Health Organization.

For nearly 50 years, the WFH has provided global leadership to improve and sustain care for people with bleeding disorders, including hemophilia, von Willebrand’s disease, rare factor defi ciencies, and platelet disorders.

| Fall 2012

HEM493219-01.indd 1 10/11/12 4:24 PM

On February 11, 1997, BeneFix®

Coagulation Factor IX (Recombinant) was approved for the treatment of hemophilia B. Today, with more than 5 billion IU manufactured and approval in 51 countries worldwide, BeneFix is proud to honor the experience of the community it has stood with for more than 15 years.

One of the ways in which Pfizer has sought to honor the scientists, health care providers, and community members who were vital to the development of BeneFix is through a documentary,

“Pushing Boundaries: How Science Impacted the Treatment of Hemophilia B.” The documentary chronicles changes in hemophilia treatment and the hemophilia

community over the past 80+ years as well as the development of BeneFix.

Another way in which BeneFix is honoring the hemophilia B community is by listening to the needs of patients worldwide and striving to bring them product updates that may help with their care. Two of the most recent updates are a room temperature storage condition and the first 3000-IU dose for hemophilia B patients.

These updates may give patients and caregivers more flexibility with their therapy, and, in the case of 3000 IU, patients may be able to cut down on the number of vials needed:

“With the 3000-IU dose, Peyton is comfortable reconstituting because he doesn’t have to switch vials, which has always been tricky for him.”

–Mother of a hemophilia B patient on what the 3000-IU dose means for her 9-year-old son

Xyntha® Antihemophilic Factor (Recombinant), Plasma/Albumin-Free has been demonstrated in clinical trials to control bleeds • On demand with 1 or 2 infusions• During and after surgery• Demonstrated low inhibitor rate

Clinical response to XynTHA may vary. If bleeding is not controlled with the recommended dose of factor, determine the plasma level and administer a dose of XynTHA sufficient to achieve clinical response.

XynTHA SOLOFUSE may help simplify the reconstitution process for those patients who are learning to self-administer their factor. now, have a look at what these XynTHA SOLOFUSE patients have to say.

ENRIQUE: I liked the device; there’s nothing else out there like that. I’m a very active guy and so to have that one syringe, it’s nice. I like the fact that it’s compact and I can fit it into my backpack.

ELLIS: I didn’t believe that you could actually

If the factor level does not increase or there is no response, suspect an inhibitor and perform appropriate testing.

XynTHA® SOLOFUSE® is the only reconstitution device for hemophilia A patients with an all-in-one design • Preloaded with XynTHA and diluent

to eliminate the transfer step for fast and easy reconstitution

• Available in 5 dosing options• Packaged in a travel-ready kit with

everything patients need to infuse

do everything within one vial; it mixes so fast, and I was skeptical at first, but it really came together quite nicely. With the other item I had been taking before, I had to carry syringes, needles, gauze—all things separate from the actual product. now, it’s all within one box, so it’s very easy to pack.

If you feel as if you have patients who may be appropriate candidates for XynTHA SOLOFUSE, contact your Pfizer Hemophilia representative. Please visit PfizerHemophilia.com for more information on XynTHA SOLOFUSE.

XYNTHA SOLOFUSE: UNLEASHiNg rEcONSTiTUTiON cONvENiENcE

BeneFix: 15+ yEaRS oF REcomBINaNt FactoR IX thERapy*

“ ...it’s all within one box, so it’s very easy to pack.”

Manufactured by Wyeth Pharmaceuticals Inc.HEM493219-01 © 2012 Pfizer Inc. All rights reserved.

Marketed by Pfizer Inc.Printed in USA/October 2012

†OFFER TERMS: By using the Pfizer Factor Savings Card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below: The Card is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare or any other federal or state healthcare programs (including any state prescription drug assistance programs and the Government Health Insurance Plan, available in Puerto Rico, formerly known as “La Reforma de Salud”). The Card is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs which reimburse you for the entire cost of your prescription drugs. you will receive a total benefit of $500 over 12 months, or the amount of your co-pay over 12 months less a patient financial responsibility of $10 per month, whichever is less. you must deduct the value of this offer from any reimbursement requests submitted to your insurance plan either by you or on your behalf. The Card is not valid where otherwise prohibited by law. The Card cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription. The card will be accepted only at participating pharmacies. This coupon is not health insurance. Offer good only in the U.S. and Puerto Rico. The Card is limited to 1 per person during this offering period and is not transferable. Offer limited to one use per month up to 12 times per patient per year. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. Offer expires 12/31/13. no membership fees.

‡OFFER TERMS: By enrolling in the Pfizer Factor Product Trial Prescription Program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below: you are currently covered by a private [commercial] insurance plan. An original free trial offer and a valid prescription must be presented. no claim for reimbursement for Pfizer factor products dispensed pursuant to this free trial offer may be submitted to any third-party payor. Medicaid, Medicare, or any other federal or state health care program beneficiaries are not eligible for this offer (this includes any state prescription drug assistance programs and Government Health Insurance Plan, available in Puerto Rico, formerly known as “La Reforma de Salud”). The free trial offer is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or health or pharmacy benefit programs that reimburse you for the entire cost of your prescription drugs. This free trial offer is not valid where otherwise prohibited by law. you will receive a 1-month supply up to 20,000 IU of factor. The free trial offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the prescribed prescription. The free trial offer will only be accepted by participating factor providers. This free trial offer is not health insurance. Offer good only in the U.S. and Puerto Rico. Only new patients may use this offer. By redeeming this offer, you certify that you are not currently using Pfizer factor products. Only 1 offer per person may be redeemed under this program. This offer is not transferable. Pfizer reserves the right to rescind, revoke, or amend this free trial offer without notice. Offer expires 1 month from enrollment date or when the maximum benefit up to 20,000 IU at no cost has been reached. no membership fees.

indication for XYNTHAXyntha® antihemophilic Factor (Recombinant), plasma/albumin-Free is indicated for the control and prevention of bleeding episodes in patients with hemophilia a (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia a.

XyNtha does not contain von Willebrand factor and, therefore, is not indicated in von Willebrand’s disease.

important Safety information for XYNTHA• Do not use in patients who have manifested life-threatening immediate hypersensitivity reactions,

including anaphylaxis, to the product or its components, including hamster proteins.

• allergic-type hypersensitivity reactions are possible. Inform patients of the early signs or symptoms (including hives, generalized urticaria, chest tightness, wheezing, and hypotension) and anaphylaxis. If these symptoms occur, advise patients to discontinue use of the product and contact their physician. XyNtha contains trace amounts of hamster proteins. patients may develop hypersensitivity to these proteins.

• patients using coagulation factor VIII products should be monitored for inhibitors, which have been reported in patients receiving XyNtha.

• clinical response to XyNtha may vary. If bleeding is not controlled with the recommended dose of factor, determine the plasma level and administer a dose of XyNtha sufficient to achieve clinical response. If the factor level does not increase or there is no response, suspect an inhibitor and perform appropriate testing.

• the most common adverse reaction in the safety and efficacy study is headache (24% of subjects) and in the surgery study is fever (43% of subjects). overall, the most common adverse reactions (≥5% of subjects) in clinical studies were headache, fever, nausea, vomiting, diarrhea, and weakness.

• XyNtha is an injectable medicine administered by intravenous (IV) infusion. patients should be advised that local irritation may occur when infusing XyNtha after reconstitution in XyNtha® SoLoFUSE®.

indication for BeneFixBeneFix® coagulation Factor IX (Recombinant) is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with hemophilia B (congenital factor IX deficiency or christmas disease), including peri-operative management.

BeneFix is NOT indicated for the treatment of other factor deficiencies (eg, factors II, VII, VIII and X), hemophilia a patients with inhibitors to factor VIII, reversal of coumarin-induced anticoagulation, or bleeding due to low levels of liver-dependent coagulation factors.

Please see accompanying full Prescribing information for XYNTHA and XYNTHA SOLOFUSE. Please see accompanying full Prescribing information for BeneFix.

As hemophilia patients around the world continue on their individual treatment journeys, BeneFix is proud to stand with the hemophilia B community.

For more information on BeneFix, please visit PfizerHemophilia.com. *BeneFix was approved February 11, 1997.

BeneFix 3000 IU. The first 3000-IU dose for hemophilia B patients.

important Safety information for BeneFix• BeneFix is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity

reactions, including anaphylaxis, to the product or its components, including hamster protein.

• anaphylaxis and severe hypersensitivity reactions are possible. Should symptoms occur, treatment with the product should be discontinued, and emergency treatment should be sought.

• BeneFix has been associated with the development of thromboembolic complications, including patients receiving continuous infusion through a central venous catheter. the safety and efficacy of BeneFix administration by continuous infusion have not been established.

• Development of activity-neutralizing antibodies has been detected in patients receiving factor IX products. If expected plasma factor IX activity levels are not attained, or if patient presents with allergic reaction, or if bleeding is not controlled with an expected dose, an assay that measures factor IX inhibitor concentration should be performed.

• patients may develop hypersensitivity to hamster (cho) protein as BeneFix contains trace amounts.

• the most common adverse reactions (>5%) from clinical trials were nausea, injection site reaction, injection site pain, headache, dizziness and rash.

For more information, please visit PfizerHemophilia.com

helping your patients get the therapy they need†

When it comes to your patients, cost, quality, and convenience are of the utmost importance. The Pfizer Factor Savings card is designed to help eligible patients save on their Pfizer factor products, with up to $500 annually toward co-pay, deductible, and coinsurance costs.

For your eligible hemophilia patients

pfizer hemophilia offers the trial prescription program‡

Appropriate patients may be eligible to receive a one-time, 1-month supply up to 20,000 iU of recombinant therapy at no cost.For commercially insured only. medicare/medicaid beneficiaries are not eligible.

Visit PfizerHemophilia.com for more information on the Trial Prescription Program.

†terms and conditions apply. ‡terms and conditions apply.

If you have any questions about the use of this Pfizer Factor Savings Card, please call 1-888-240-9040 or send questions to: Pfizer Factor Savings Program, 6501 Weston Parkway, Suite 370, Cary, NC 27513. Pfizer Factor Savings Card cannot be combined with other offers.

Visit PfizerHemophilia.com for more information on the Pfizer Factor Savings Card program.

HEM493219-01.indd 2 10/11/12 4:24 PM